November 21, 2018 Acad, Gov/Utilities Product Launch

Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy

Basel, 21 November 2018 Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy Approval based on two studies that showed durable remissions in people with newly-diagnosed acute myeloid leukaemia, who are age 75 years or older, or for those ineligible for... Read more

November 1, 2018 Bio/Pharma/CRO PR/Corporate

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities

Basel, 01 November 2018 Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities The phase III CLL14 study compared Venclexta/Venclyxto in combination with Gazyva/Gazyvaro to standard-of-care Gazyva/Gazyvaro plus chlorambucil Data will be submitted to health authorities and presented... Read more

October 16, 2018 Clinical Research/Diagn.

Reminder: Invitation to Roche's live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress

Basel, 16 October 2018 Reminder: Invitation to Roche’s live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Monday, 22 October 2018, to discuss key data presented on the Roche Group’s oncology portfolio and pipeline during the... Read more

October 15, 2018 Clinical Research/Diagn. M&A, Partnerships

Roche Diagnostics partners with DASA Group to create the world’s largest integrated core lab* today

Partnership that grows stronger While DASA has experienced unprecedented growth and success with their integrated lab, they don’t plan on slowing down. Alessandro Veiga states, “We haven’t stopped growing. DASA has an expectation to become a global leader in diagnostic medicine throughout the world.” DASA Group’s vision is to be the best company in the... Read more

October 15, 2018 Clinical Research/Diagn. Life Science Tools Product Launch

Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research

Basel, 15 October 2018 Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research Ready-to-use kits determine genomic characteristics of solid tumours Optimized workflow to generate results in house Software analysis allows correlation to AVENIO ctDNA NGS kits Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global commercial launch of three new next-generation... Read more

October 10, 2018 Licensing, IP, and Legal PR/Corporate

OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis

Basel, 10 October 2018 OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis People with relapsing MS (RMS) treated sooner with OCREVUS had earlier reduction in disease activity and less disability progression vs. those who switched from interferon beta-1α People with primary progressive... Read more

October 4, 2018 Bio/Pharma/CRO PR/Corporate

Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018

Basel, 04 October 2018 Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018 Baloxavir marboxil – a first-in-class, single-dose, investigational oral medicine – is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable... Read more

September 24, 2018 Bio/Pharma/CRO

Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid

Basel, 24 September 2018 Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid Liquid biopsy test can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability Many cancer patients have insufficient or inadequate tissue for genomic testing and so may benefit from FoundationOne Liquid FoundationOne Liquid... Read more

September 21, 2018 Bio/Pharma/CRO

CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis

Basel, 21 September 2018 CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the subcutaneous... Read more